High levels of vitamin D in relation to reduced risk of schizophrenia with elevated C-reactive protein

Psychiatry Research

Volumn 228, Issue 3, 2015, Pages 565-570

  Zhu, Dao min ^a,b,c   Liu, Yong ^a,b,c   Zhang, Ai guo ^a,b,c   Chu, Zhao xue ^a,b,c   Wu, Qing ^a,b,c   Li, Hui ^a,b,c   Ge, Jin fang ^b   Dong, Yi ^a,b,c   Zhu, Peng ^b,d  

^a People's Hospital of Hefei   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c SHANDONG MENTAL HEALTH CENTER   (China)

^d ANHUI PROVINCIAL KEY LABORATORY OF POPULATION HEALTH AND ARISTOGENICS   (China)

Author keywords

25 hydroxyvitamin D; C reactive protein; Inflammation; Schizophrenia; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; VITAMIN D; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; FEMALE; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK REDUCTION; SCHIZOPHRENIA; SOCIAL STATUS; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; YOUNG ADULT; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; INFLAMMATION; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADOLESCENT; ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; VITAMIN D; YOUNG ADULT;

EID: 84938751504     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.05.051     Document Type: Article

References (37)

1. Akanji A.O., Ohaeri J.U., Al-Shammri S., Fatania H.R. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Research 2009, 169:56-61.
2. Amer M., Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). The American Journal of Cardiology 2012, 109:226-230.
3. Bellia A., Garcovich C., D'Adamo M., Lombardo M., Tesauro M., Donadel G., Gentileschi P., Lauro D., Federici M., Lauro R., Sbraccia P. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Internal and Emergency Medicine 2013, 8:33-40.
4. Benros M., Nielsen P., Nordentoft M., Eaton W., Dalton S., Mortensen P. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. The American Journal of Psychiatry 2011, 168:1303.
5. Benros M.E., Mortensen P.B., Eaton W.W. Autoimmune diseases and infections as risk factors for schizophrenia. Annals of the New York Academy of Sciences 2012, 1262:56-66.
6. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. The American Journal of Psychiatry 2014, 168:1303.
7. Bjorkman M., Sorva A., Tilvis R. C-reactive protein and fibrinogen of bedridden older patients in a six-month vitamin D supplementation trial. The Journal of Nutrition, Health and Aging 2009, 13:435-439.
8. Blomström Å., Karlsson H., Svensson A., Frisell T., Lee B.K., Dal H., Magnusson C., Dalman C. Hospital admission with infection during childhood and risk for psychotic illness-a population-based cohort study. Schizophrenia Bulletin 2014, 40:1518-1525.
9. Brewer L.D., Thibault V., Chen K.C., Langub M.C., Landfield P.W., Porter N.M. Vitamin D hormone confers neuroprotection in parallel with downregulation of l-type calcium channel expression in hippocampal neurons. The Journal of Neuroscience 2001, 21:98-108.
10. Dalman C., Allebeck P., Gunnell D., Harrison G., Kristensson K., Lewis G., Lofving S., Rasmussen F., Wicks S., Karlsson H. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. American Journal of Psychiatry 2008, 165:59-65.
11. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yang S., Yolken R. C-reactive protein is elevated in schizophrenia. Schizophrenia Research 2013, 143:198-202.
12. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., Mortensen P.B. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. The American Journal of Psychiatry 2006, 163:521-528.
13. Fawzi M.H., Fawzi M.M., Fawzi M.M., Said N.S. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Research 2011, 190:91-97.
14. ® Axis I Disorders (SCID-I), Clinician Version, Administration Booklet 2012, American Psychiatric Pub, Washington, D.C.
15. Han T.S., Sattar N., Williams K., Gonzalez-Villalpando C., Lean M.E.J., Haffner S.M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico city diabetes study. Diabetes Care 2002, 25:2016-2021.
16. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 2009, 71:171-186.
17. Jorde R., Sneve M., Torjesen P.A., Figenschau Y., Gøransson L.G., Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010, 50:175-180.
18. Kesby J.P., Eyles D.W., Burne T.H., McGrath J.J. The effects of vitamin D on brain development and adult brain function. Molecular and Cellular Endocrinology 2011, 347:121-127.
19. Kuhlmann C.R., Librizzi L., Closhen D., Pflanzner T., Lessmann V., Pietrzik C.U., de Curtis M., Luhmann H.J. Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke 2009, 40:1458-1466.
20. Kuo H.-K., Yen C.-J., Chang C.-H., Kuo C.-K., Chen J.-H., Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. The Lancet Neurology 2005, 4:371-380.
21. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., Ochoa M.T., Schauber J., Wu K., Meinken C., Kamen D.L., Wagner M., Bals R., Steinmeyer A., Zugel U., Gallo R.L., Eisenberg D., Hewison M., Hollis B.W., Adams J.S., Bloom B.R., Modlin R.L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
22. McGrath J., Saari K., Hakko H., Jokelainen J., Jones P., Jarvelin M.R., Chant D., Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophrenia Research 2004, 67:237-245.
23. Ngo D.T., Sverdlov A.L., McNeil J.J., Horowitz J.D. Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations?. The American Journal of Medicine 2010, 123:335-341.
24. Pedrini M., Massuda R., Fries G.R., de Bittencourt Pasquali M.A., Schnorr C.E., Moreira J.C., Teixeira A.L., Lobato M.I., Walz J.C., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. Journal of Psychiatric Research 2012, 46:819-824.
25. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 2001, 286:327-334.
26. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England journal of medicine 2002, 347:1557-1565.
27. Roberts W.L., Sedrick R., Moulton L., Spencer A., Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clinical Chemistry 2000, 46:461-468.
28. Rott R., Herzog S., Fleischer B., Winokur A., Amsterdam J., Dyson W., Koprowski H. Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science 1985, 228:755-756.
29. Satizabal C., Zhu Y., Mazoyer B., Dufouil C., Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly The 3C-Dijon Study. Neurology 2012, 78:720-727.
30. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. The American Journal of Clinical Nutrition 2006, 83:754-759.
31. Spitzer R.L., Gibbon M., Williams J.B. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version 1997, American Psychiatric Pub.
32. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. Journal of Autoimmunity 2006, 27:71-80.
33. Suvisaari J., Loo B.M., Saarni S.E., Haukka J., Perala J., Saarni S.I., Viertio S., Partti K., Lonnqvist J., Jula A. Inflammation in psychotic disorders: a population-based study. Psychiatry Research 2011, 189:305-311.
34. Wersching H., Duning T., Lohmann H., Mohammadi S., Stehling C., Fobker M., Conty M., Minnerup J., Ringelstein E.B., Berger K., Deppe M., Knecht S. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010, 74:1022-1029.
35. Wium-Andersen M.K., Orsted D.D., Nordestgaard B.G. Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study. Schizophrenia Bulletin 2014, 40:1117-1127.
36. Zhang Y., Leung D.Y., Richers B.N., Liu Y., Remigio L.K., Riches D.W., Goleva E. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. The Journal of Immunology 2012, 188:2127-2135.
37. Zhou B.F. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Chinese Journal of Epidemiology 2002, 23:5-10.